Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Rating of “Buy” from Analysts

Oruka Therapeutics, Inc. (NASDAQ:ORKA) has been assigned an average recommendation of “Buy” from the ten research firms that are currently covering the firm, Marketbeat.com reports. Eight investment analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $40.38.

Several brokerages have commented on ORKA. BTIG Research began coverage on Oruka Therapeutics in a research note on Thursday, May 22nd. They set a “buy” rating for the company. Wedbush restated an “outperform” rating and set a $40.00 price target on shares of Oruka Therapeutics in a research note on Thursday, May 15th. Finally, Wall Street Zen upgraded Oruka Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, June 22nd.

Oruka Therapeutics Trading Up 3.3%

NASDAQ ORKA opened at $14.70 on Tuesday. The business’s 50-day moving average price is $11.66 and its 200 day moving average price is $11.71. Oruka Therapeutics has a twelve month low of $5.49 and a twelve month high of $31.13. The company has a market capitalization of $550.37 million, a PE ratio of -3.26 and a beta of -0.34.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.17. Equities analysts predict that Oruka Therapeutics will post -3.41 EPS for the current year.

Institutional Investors Weigh In On Oruka Therapeutics

A number of large investors have recently modified their holdings of ORKA. JPMorgan Chase & Co. purchased a new position in Oruka Therapeutics in the fourth quarter valued at about $54,000. AlphaQuest LLC purchased a new position in Oruka Therapeutics in the first quarter valued at about $168,000. Cannon Global Investment Management LLC purchased a new position in Oruka Therapeutics in the first quarter valued at about $195,000. Squarepoint Ops LLC purchased a new position in Oruka Therapeutics in the fourth quarter valued at about $236,000. Finally, Charles Schwab Investment Management Inc. purchased a new position in Oruka Therapeutics in the fourth quarter valued at about $303,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.